Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 1
2003 3
2004 1
2006 1
2008 1
2009 1
2011 1
2012 1
2013 2
2015 1
2016 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

12 results
Results by year
Filters applied: . Clear all
Page 1
What is nocturnal polyuria?
Rembratt A, Norgaard JP, Andersson KE. Rembratt A, et al. BJU Int. 2002 Dec;90 Suppl 3:18-20. doi: 10.1046/j.1464-410x.90.s3.5.x. BJU Int. 2002. PMID: 12445094 Review. No abstract available.
Pharmacokinetic and tolerability profile of pridopidine in healthy-volunteer poor and extensive CYP2D6 metabolizers, following single and multiple dosing.
Lindskov Krog P, Osterberg O, Gundorf Drewes P, Rembratt Å, Schultz A, Timmer W. Lindskov Krog P, et al. Among authors: rembratt a. Eur J Drug Metab Pharmacokinet. 2013 Mar;38(1):43-51. doi: 10.1007/s13318-012-0100-2. Epub 2012 Sep 5. Eur J Drug Metab Pharmacokinet. 2013. PMID: 22948856 Clinical Trial.
Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial.
de Yebenes JG, Landwehrmeyer B, Squitieri F, Reilmann R, Rosser A, Barker RA, Saft C, Magnet MK, Sword A, Rembratt A, Tedroff J; MermaiHD study investigators. de Yebenes JG, et al. Among authors: rembratt a. Lancet Neurol. 2011 Dec;10(12):1049-57. doi: 10.1016/S1474-4422(11)70233-2. Epub 2011 Nov 7. Lancet Neurol. 2011. PMID: 22071279 Clinical Trial.
12 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page